NCT07339475 Femoral Vein Diameter to Predict Intraoperative Hypotension in Geriatric Patients Undergoing Orthopedic Surgery Under Spinal Anesthesia
| NCT ID | NCT07339475 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Femoral Vein Diameter |
| Study Type | OBSERVATIONAL |
| Enrollment | 43 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 43 participants in total. It began in 2025-12-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to assess whether the transverse diameter of the right common femoral vein (RCFV) in the inguinal region could reflect the degree of post-spinal hypotension during elective orthopedic surgery.
Eligibility Criteria
Inclusion Criteria: * Age \> 60 years. * American Society of Anesthesiologists (ASA) physical state I-II. * Body mass index (BMI) ≤35 kg/m². Patients above this value will be excluded because obesity may cause technical difficulty and poor image quality in femoral vein ultrasound assessment. * Elective lower-limb orthopedic surgery under spinal anesthesia. Exclusion Criteria: * Patients refusing to participate. * History of psychiatric illness or seizures. * Absolute contraindications to spinal anesthesia: infection at the puncture site, severe coagulopathy/anticoagulation \[defined as platelet count \<75,000/µL, International Normalized Ratio (INR) \>1.5, Activated Partial Thromboplastin Time (aPTT) \>1.5 times control, or the use of anticoagulants such as warfarin, heparin, low molecular weight heparin, or direct oral anticoagulants within the recommended safety interval for neuraxial anesthesia\], severe hypovolemia, increased intracranial pressure, or known allergy to local anesthetics. * Severe cardiac disease, including left ventricular ejection fraction \<30%, Severe valvular heart disease (e.g., critical aortic stenosis), clinically significant arrhythmias (atrial fibrillation with uncontrolled ventricular rate \>120 bpm, frequent ventricular ectopy or sustained ventricular tachyarrhythmia) and congestive heart failure such as New York Heart Association (NYHA) class III-IV. * Severe uncontrolled hypertension, defined as persistent mean arterial pressure (MAP) ≥120 mmHg or systolic blood pressure (SBP) ≥180 mmHg and/or diastolic blood pressure (DBP) ≥110 mmHg despite medical therapy. * Severe respiratory diseases (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage III-IV chronic obstructive pulmonary disease, or forced vital capacity (FVC) \<50% predicted). * Baseline bradycardia (\<50) or mean arterial blood pressure less than 60mmHg. * Emergency surgeries.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07339475 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Femoral Vein Diameter. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07339475 currently recruiting?
Yes, NCT07339475 is actively recruiting participants. Contact the research team at drhebasalah593@gmail.com for enrollment information.
Where is the NCT07339475 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07339475 clinical trial?
NCT07339475 is sponsored by Cairo University. The trial plans to enroll 43 participants.